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OBJECTIVE—Genetic factors are believed to contribute to the
development and progression of diabetic nephropathy. Recently,
a genome-wide association study for diabetic nephropathy re-
vealed four novel candidate loci in European American subjects
with type 1 diabetes. In this study, we determined the association
of the four loci with diabetic nephropathy in Japanese subjects
with type 2 diabetes.
RESEARCH DESIGN AND METHODS—We genotyped 11
singlenucleotide polymorphisms (SNPs) in four distinct loci
(rs39059 and rs39075 in the CPVL/CHN2, rs1888747 and rs10868025
in FRMD3, rs739401 and rs451041 in CARS, and rs1041466,
rs1411766, rs6492208, rs7989848, and rs9521445 in a chromosome
13q locus) in four independent Japanese populations.
RESULTS—Six SNPs were nominally associated with diabetic
nephropathy in one of the four Japanese populations (P  0.05;
rs451041 in study 1; rs39059 and rs1888747 in study 3; rs1411766
in studies 1 and 4; and rs7989848 and rs9521445 in study 4);
however, no signiﬁcant association was observed for any SNP
after correction for multiple testing errors in the individual
populations. Nevertheless, a meta-analysis performed for the
data obtained from all four populations revealed that one SNP
(rs1411766) in chromosome 13q was signiﬁcantly associated with
diabetic nephropathy in the Japanese populations (nominal P 
0.004, corrected P  0.04, odds ratio 1.26 [95% CI  1.07–1.47]).
CONCLUSIONS—Our results suggest that the rs1411766 locus
may be commonly involved in conferring susceptibility to dia-
betic nephropathy among subjects with type 1 or type 2 diabetes
across different ethnic groups. Diabetes 59:2075–2079, 2010
D
iabetic nephropathy is a leading cause of end-
stage renal disease in Western countries (1) and
in Japan (2). Several genetic and environmental
factors are likely to contribute to its develop-
ment and progression (3,4), but the precise mechanism for
this contribution is unknown.
Both candidate gene approaches and genome-wide link-
age analyses have suggested several candidate genes with
potential impact on diabetic nephropathy. However, these
ﬁndings have not been robustly replicated (5,6), and many
genes responsible for susceptibility to diabetic nephropa-
thy remain to be identiﬁed.
To identify loci involved in susceptibility to common
diseases, we initiated a large-scale association study using
single nucleotide polymorphisms (SNPs) from a Japanese
SNP database (http://snp.ims.u-tokyo.ac.jp/index_ja.html)
(7,8). Through this project, we have previously identiﬁed
genes encoding solute carrier family 12 (sodium/chloride)
member 3 (SLC12A3, MIM 600968, http://www.ncbi.nlm.
nih.gov/omim]) (9); engulfment and cell motility 1
(ELMO1, MIM 606420) (10); neurocalcin  (NCALD, MIM
606722) (11); and acetyl-CoA carboxylase beta gene
(ACACB, MIM 601557) (12) as being associated with
susceptibility to diabetic nephropathy. The association of
ELMO1 with diabetic nephropathy has been conﬁrmed in
African Americans (13) and European Americans (14).
The recent genome-wide association studies (GWASs)
using populations in the Genetics of Kidneys in Diabetes
(GoKinD) collection led to the identiﬁcation of four dis-
tinct loci as novel candidate loci for susceptibility to
diabetic nephropathy in European American subjects with
type 1 diabetes (15): the CPVL/CHN2 locus on chromo-
some 7, the FRMD3 locus on chromosome 9, the CARS
locus on chromosome 11, and a locus near IRS2 on
chromosome 13. Because the frequencies of some genetic
variations are known to signiﬁcantly differ among ethnic
groups, it is now necessary to evaluate the role of these
loci in conferring susceptibility to diabetic nephropathy in
other ethnic populations.
To determine whether the genetic variations identiﬁed
through the GWASs on European Americans with type 1
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nephropathy in Japanese individuals with type 2 diabetes,
we studied the association between the SNPs in the above
four loci and diabetic nephropathy in Japanese subjects
with type 2 diabetes.
RESEARCH DESIGN AND METHODS
Subjects, DNA preparation, and SNP genotyping
Study 1. DNA samples were obtained from the peripheral blood of patients
with type 2 diabetes who regularly visited the outpatient clinics at Shiga
University of Medical Science, Tokyo Women’s Medical University, Juntendo
University, Kawasaki Medical School, Iwate Medical University, Toride Kyodo
Hospital, Kawai Clinic, Osaka City General Hospital, Chiba Tokushukai
Hospital, or Osaka Rosai Hospital. Diabetes was diagnosed according to the
World Health Organization criteria. Type 2 diabetes was clinically deﬁned as
a disease with gradual adult onset. Subjects who tested positive for anti-GAD
antibodies and those diagnosed with mitochondrial disease (mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke-like episodes [MELAS])
or maturity onset diabetes of the young (MODY) were not included. The
patients were divided into two groups: 1) the nephropathy group (n  754,
mean  SE age 60.1  0.4 years, diabetes duration 19.3  0.4 years, BMI
23.7  0.2 kg/m
2) comprised patients with diabetic retinopathy and overt
nephropathy indicated by a urinary albumin excretion rate (AER) 200
g/min or a urinary albumin-to-creatinine ratio (ACR) 300 mg/g creatinine
(Cr) and 2) the control group (n  558, age 62.4  0.5 years, diabetes duration
15.3  0.4 years, BMI 23.6  0.2 kg/m
2) comprised patients who had diabetic
retinopathy but no evidence of renal dysfunction (i.e., AER 20 g/min or
ACR30 mg/g Cr). The AER or ACR were measured at least twice for each
patient.
Study 2. We selected diabetic nephropathy patients and control patients
among the subjects enrolled in BioBank Japan. Nephropathy cases were
deﬁned as patients with type 2 diabetes having both overt diabetic nephrop-
athy and diabetic retinopathy (n  449, age 64.7  0.4 years, BMI 23.5  0.2
kg/m
2). The control subjects were patients with type 2 diabetes who had
diabetic retinopathy and normoalbuminuria (n  965, age 64.8  0.3 years,
BMI 23.8  0.1 kg/m
2).
Study 3. Patients with type 2 diabetes were recruited from the participants of
the Shiga Prospective Observational Follow-up Study for Diabetic Complica-
tions (16). Patients classiﬁed as having microalbuminuria (200 g/min 
AER  20 g/min) on the basis of at least two measurements of AER in 24-h
urine collections were followed-up for up to 6 years. Patients in whom the
condition progressed to overt proteinuria (AER 200 g/min) were classiﬁed
as progressors (case subjects: n  32, age 60.9  1.7 years, diabetes duration
14.5  1.6 years, BMI 24.9  0.5 kg/m
2) and the remaining patients were
deﬁned as nonprogressors (control subjects: n  168, age 60.4  0.7 years,
diabetes duration 12.8  0.7 years, BMI 23.9  0.3 kg/m
2).
Study 4. Patients with type 2 diabetes who regularly visited Tokai University
Hospital or its afﬁliated hospitals were enrolled in this study. All the
nephropathy patients (n  300, age 64.4  0.6 years, diabetes duration 21.9 
0.9 years, BMI 22.1  0.2 kg/m
2) were receiving chronic hemodialysis therapy,
and the control patients (n  224, age 65.0  0.7 years, diabetes duration
16.3  0.4 years, BMI 23.4  0.3 kg/m
2) included those with normoalbumin-
uria, determined by at least two measurements of the urinary ACR, and
diabetes for more than 10 years.
All the patients participating in this study provided written informed
consent, and the study protocol was approved by the ethics committees of
RIKEN Yokohama Institute and of each participating institution.
The clinical characteristics of the subjects are shown in supplementary
Table 1 in the online appendix available at http://diabetes.diabetesjournals.
org/cgi/content/full/db10-0067/DC1.
Among 13 SNPs previously reported, 11 SNPs were genotyped using
multiplex PCR-invader assays, as described previously (9–12). Because
rs17412858 and rs2391777 were in absolute linkage disequilibrium (LD) (r
2 
1) to rs1411766 and rs6492208, respectively, these two SNPs were excluded
from the present analyses. Overall success rates of the present assay are
95%, and the concordance rates in selected duplicate samples are 100% for
all examined SNPs.
Statistical analyses. We tested the genotype distributions for Hardy-Wein-
berg equilibrium (HWE) proportions by using the 
2 test (17). We analyzed the
differences between the case and control groups in terms of the distribution
of genotypes with an allelic model by using a logistic regression analysis.
Combined meta-analysis was performed using the Mantel-Haenszel test with a
ﬁxed-effects model or the DerSimonian-Laird method with a random-effects
model after testing for heterogeneity.
RESULTS
Among the 11 SNPs examined in the present study, 4 SNPs
showed modest deviation from HWE in either the case or
control groups (rs451041 and rs739401 in the study 2
control group, rs1411766 in the study 4 case group, and
rs1041466 in the case groups of studies 1 and 2; see
supplementary Table 2). Regarding two SNPs with modest
deviation from HWE in the control group, genotype distri-
bution of combined population (case and control groups in
study 2) were in HWE (P  0.20, P  0.36, respectively);
therefore, we included these data in the present analyses.
As shown in Table 1, six SNPs were observed to be
nominally associated with diabetic nephropathy in one of
the four studies (P  0.05, rs39059 and rs1888747 in study
3, rs451041 in study 1, rs1411766 in studies 1 and 4,
rs7989848 and rs9521445 in study 4). However, none of the
examined SNPs exhibited a signiﬁcant association with
diabetic nephropathy in the individual studies after the
correction for multiple testing errors. By combining the
results of all four studies by a meta-analysis, however, we
determined that rs1411766 on chromosome 13q was sig-
niﬁcantly associated with diabetic nephropathy (nominal
P  0.004, corrected P  0.04, odds ratio [OR]  1.26 [95%
CI 1.07–1.47]; Table 2) with the same direction of the
association as previously described by Pezzolesi et al. We
further performed the meta-analysis to combine the
present Japanese results with the data previously reported
in European American type 1 diabetes. The results indi-
cated that signiﬁcant heterogeneities were present for ORs
of most SNPs examined in this study, except for rs1411766
and rs1041466, between the Japanese type 2 diabetes and
European American type 1 diabetes, and that the associa-
tion of rs1411766 with diabetic nephropathy attained ge-
nome-wide signiﬁcance levels (Table 3).
DISCUSSION
In the present study, we examined four independent
Japanese populations to determine the association of four
candidate loci with diabetic nephropathy; these loci had
been identiﬁed through a GWAS on European American
subjects with type 1 diabetes. A SNP (rs1411766) in
chromosome 13 was observed to be associated with
susceptibility to diabetic nephropathy in the Japanese
populations.
GWAS conducted in European and East Asian popula-
tions have revealed multiple risk-associated loci for many
common diseases, including type 2 diabetes (18–21). The
success of these studies has conﬁrmed that GWAS is a
useful and promising approach for identifying susceptibil-
ity genes for common complex traits. Many susceptibility
loci identiﬁed through GWAS have been conﬁrmed, and
these loci have been shown to be common across different
ethnic groups (22,23); however, for considerable number
of loci, the associations have not been shown to consis-
tently hold true for different ethnic populations (24).
In the present study, we could replicate the results for
only one of the four loci from GWAS in European Ameri-
can type 1 diabetes. Because the trend observed in the
association of rs1411766 with diabetic nephropathy in our
study is consistent with that in a previous report (15), this
locus is likely to be a common susceptibility locus for
diabetic nephropathy in the case of European American
patients with type 1 diabetes and Japanese patients with
type 2 diabetes. Interestingly, in this chromosome 13q
locus, only one SNP (rs1411766) of ﬁve SNPs was signiﬁ-
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subjects with type 2 diabetes, whereas the other four SNPs
did not exhibit any association with the disease. When we
reviewed the HapMap database (http://www.hapmap.org/
index.html), we observed that rs1411766 was in moderate
LD to rs1041466 (r
2  0.55 in JPT) and in lower LD with
the other three SNPs (r
2  0.12–0.20 in JPT, 0.30–0.37 in
CEU, see supplementary Fig. 1); this suggested that
rs1411766 was more directly linked to causative
variations.
In this study, for the remaining three loci, the statistical
power to detect true association of the present study is
estimated to be 0.95 in the case of SNPs with a minor
allele frequency 0.2–0.5 under the following conditions: 1)
the cutoff value is set at a signiﬁcant level after Bonferro-
ni’s correction (P  0.0044), 2) there is a genotypic relative
risk () of 1.3–1.4, and 3) the prevalence of diabetic
nephropathy is assumed to be 10% (CaTS power calcula-
tor, http://www.sph.umich.edu/csg/abecasis/CaTS/). In ad-
dition, combined analyses of the present data with data
from the original study by Pezzolesi et al. (15) using the
Mantel-Haenszel test did not further strengthen the origi-
nal associations of these three loci with diabetic nephrop-
athy (Table 3), whereas the association of rs1411766 with
the disease became more signiﬁcant (P  4.9 	 10

8,O R
1.34 [95% Cl 1.21–1.49]). Therefore, the effects of these
three loci might be speciﬁc for populations with a Euro-
pean ancestry or for subjects with type 1 diabetes. Be-
cause the association of these loci did not attain the
genome-wide signiﬁcance levels (5 	 10

8) in the origi-
nal report (15), further replication studies in type 1 diabe-
tes are necessary to know whether those loci are true
TABLE 1
Association of candidate SNPs with diabetic nephropathy in 4 independent Japanese populations
SNP (risk allele)*
position†
Study 1 Study 2 Study 3 Study 4
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs39059 (A) 0.11 1.14 (0.97–1.35) 0.83 0.98 (0.84–1.15) 0.03 1.93 (1.08–3.42) 0.39 1.12 (0.87–1.43)
Ch7, 29255470 0.15‡ 1.16 (0.95–1.43) 0.88‡ 1.01 (0.86–1.20) 0.26‡ 1.54 (0.72–3.28) 0.83‡ 0.97 (0.72–1.30)
rs39075 (G) 0.23 1.11 (0.94–1.30) 0.94 0.99 (0.85–1.16) 0.07 1.72 (0.96–3.09) 0.44 1.10 (0.86–1.41)
Ch7, 29276692 0.14‡ 1.17 (0.95–1.43) 0.77‡ 1.03 (0.87–1.21) 0.36‡ 1.44 (0.66–3.14) 0.71‡ 0.95 (0.70–1.27)
rs1888747 (G) 0.35 1.10 (0.90–1.36) 0.86 0.98 (0.81–1.19) 0.03 0.50 (0.27–0.93) 0.12 0.79 (0.58–1.06)
Ch9, 86155551 0.10‡ 1.24 (0.96–1.61) 0.84‡ 1.02 (0.83–1.26) 0.004‡ 0.28 (0.12–0.67) 0.43‡ 0.87 (0.61–1.23)
rs10868025 (A) 0.53 1.06 (0.88–1.28) 0.41 0.93 (0.78–1.11) 0.29 0.73 (0.40–1.31) 0.26 0.86 (0.65–1.12)
Ch9, 86164176 0.31‡ 1.12 (0.89–1.42) 0.54‡ 0.94 (0.78–1.14) 0.07‡ 0.49 (0.22–1.06) 0.33‡ 0.85 (0.62–1.18)
rs739401 (C) 0.45 1.07 (0.90–1.28) 0.85 0.98 (0.83–1.16) 0.13 0.63 (0.34–1.15) 0.69 0.95 (0.73–1.23)
Ch11, 3036324 0.30‡ 1.12 (0.90–1.39) 0.91‡ 1.01 (0.85–1.21) 0.25‡ 0.62 (0.27–1.42) 0.82‡ 1.04 (0.76–1.42)
rs451041 (A) 0.11 1.17 (0.97–1.41) 0.60 1.05 (0.88–1.25) 0.25 0.69 (0.36–1.31) 0.86 0.98 (0.74–1.29)
Ch11, 3060725 0.049‡ 1.26 (1.00–1.59) 0.42‡ 1.08 (0.90–1.30) 0.26‡ 0.60 (0.25–1.46) 0.91‡ 1.02 (0.73–1.43)
rs1041466 (G) 0.11 1.26 (0.95–1.66) 0.51 1.11 (0.82–1.48) 0.16 0.35 (0.08–1.50) 0.92 0.98 (0.67–1.43)
Ch13, 110244322 0.18‡ 1.27 (0.90–1.80) 0.18‡ 1.27 (0.90–1.80) 0.12‡ 0.15 (0.01–1.59) 0.44‡ 1.20 (0.76–1.88)
rs1411766 (A) 0.045 1.33 (1.01–1.75) 0.08 1.24 (0.98–1.56) 0.75 0.86 (0.32–2.29) 0.21 1.26 (0.88–1.82)
Ch13, 110252160 0.009‡ 1.58 (1.12–2.22) 0.08‡ 1.26 (0.98–1.62) 0.33‡ 0.50 (0.12–2.01) 0.046‡ 1.55 (1.01–2.39)
rs6492208 (T) 0.61 1.05 (0.89–1.23) 0.71 0.97 (0.83–1.14) 0.68 1.13 (0.64–1.98) 0.36 1.12 (0.88–1.43)
Ch13, 110257726 0.74‡ 0.97 (0.79–1.19) 0.48‡ 0.94 (0.79–1.11) 0.82‡ 0.91 (0.40–2.05) 0.13‡ 1.25 (0.93–1.67)
rs7989848 (A) 0.75 1.03 (0.87–1.22) 0.999 1.00 (0.85–1.17) 0.79 1.08 (0.60–1.95) 0.11 1.23 (0.95–1.58)
Ch13, 110283468 0.98‡ 0.998 (0.81–1.23) 0.60‡ 0.96 (0.80–1.14) 0.55‡ 0.78 (0.34–1.78) 0.03‡ 1.42 (1.05–1.92)
rs9521445 (A) 0.76 1.03 (0.87–1.22) 0.75 1.03 (0.88–1.20) 0.97 0.99 (0.55–1.78) 0.09 1.25 (0.97–1.62)
Ch13, 110285534 0.84‡ 0.98 (0.79–1.21) 0.82‡ 0.98 (0.82–1.16) 0.45‡ 0.72 (0.30–1.69) 0.02‡ 1.45 (1.07–1.97)
*Risk allele reported in the GoKinD populations. †Data from the National Center for Biotechnology Information database (Entrez SNP,
Genome Reference Consortium Human Build 37.1; http://www.ncbi.nlm.nih.gov/sites/entrez?dbsnp). ‡Adjusted for age, sex, BMI, and
duration of type 2 diabetes in studies 1, 3, and 4, and for age, sex, and BMI in study 2.
TABLE 2
Results of a meta-analysis of four independent Japanese studies on the association of 11 SNPs with diabetic nephropathy
SNP
(risk allele)*
Proteinuria (Studies 1, 2, and 3) Proteinuria  ESRD (all studies)
P OR (95% CI)
P for
heterogeneity P OR (95% CI)
P for
heterogeneity
rs39059 (A) 0.19 1.08 (0.96–1.20) 0.06 0.12 1.08 (0.98–1.20) 0.12
rs39075 (G) 0.28 1.06 (0.95–1.19) 0.18 0.19 1.07 (0.97–1.18) 0.31
rs1888747 (G) 0.99 1.00 (0.87–1.15) 0.06 0.51 0.96 (0.85–1.09) 0.05
rs10868025 (A) 0.68 0.97 (0.86–1.10) 0.37 0.40 0.95 (0.85–1.07) 0.44
rs739401 (C) 0.96 1.00 (0.89–1.13) 0.24 0.91 0.99 (0.89–1.11) 0.38
rs451041 (A) 0.22 1.08 (0.95–1.23) 0.26 0.30 1.06 (0.95–1.19) 0.37
rs1041466 (G) 0.16 1.15 (0.95–1.41) 0.21 0.23 1.11 (0.93–1.33) 0.29
rs1411766 (A) 0.01 1.26 (1.06–1.50) 0.69 0.004 1.26 (1.07–1.47) 0.86
rs6492208 (T) 0.90 1.01 (0.90–1.13) 0.78 0.62 1.03 (0.93–1.14) 0.78
rs7989848 (A) 0.82 1.01 (0.90–1.14) 0.96 0.39 1.05 (0.94–1.16) 0.59
rs9521445 (A) 0.69 1.02 (0.91–1.15) 0.99 0.29 1.06 (0.95–1.17) 0.58
Meta-analysis was performed using the Mantel-Haenszel test. *Risk allele reported in the GoKinD populations. ESRD, end-stage renal disease.
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subjects with type 1 diabetes, phenotype determination is
likely more complicated for nephropathy study in type 2
diabetes. Therefore, phenotype differences might exist
between the US-GoKinD study and our present study.
Further investigation is required to elucidate the contribu-
tion of these loci in conferring susceptibility to diabetic
nephropathy.
In summary, we conﬁrmed the association of the A
allele of rs1411766 near the IRS2 locus on chromosome
13q with susceptibility to diabetic nephropathy in Japa-
nese subjects with type 2 diabetes. These data suggest that
this locus (rs1411766) may be a common locus involved in
susceptibility to diabetic nephropathy among patients with
type 1 or type 2 diabetes across different ethnic groups.
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